breast cancer research

Yemaachi News

October 26, 2021

Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access

PALO ALTO, Calif. & ACCRA, Ghana--(BUSINESS WIRE)--Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent.